MetaCap

Alnylam Pharmaceuticals (ALNY) vs BridgeBio Pharma (BBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BridgeBio Pharma (BBIO) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 11.6% versus a loss of 67.0%. Over five years, BBIO leads with a +92.2% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $14.81 billion), about 1.3 times the size, while BridgeBio Pharma is growing revenue faster (+126.3% vs +65.2%).

Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -146.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALNY-67.04%BBIO+11.63%
+37%-17%-72%
Nov 21, 20251 yearNov 20, 2026
ALNY-20.54%BBIO+78.26%
+179%+41%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALNY versus BBIO key metrics
MetricALNYBBIO
Share price$143.82$76.03
Market cap$19.26B$14.81B
1-day change-2.71%-2.75%
YTD return-63.83%-0.60%
1-year return-67.04%+11.63%
5-year return-23.72%+92.24%
P/E ratio (TTM)7.26—
Forward P/E14.51—
EPS (TTM)$19.80$-3.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.71B$502.08M
Revenue growth (YoY)+65.19%+126.26%
Net income (latest FY)$313.75M$-732.94M
Gross margin81.77%95.82%
Operating margin13.51%-104.25%
Net margin8.45%-145.98%
52-week high$479.79$93.42
52-week low$143.40$62.50
Distance from 52-week high-70.02%-18.61%
Analyst consensusbuystrong_buy
Avg. price target upside+101.10%+40.73%
Average volume2.09M2.67M
Shares outstanding133.94M194.80M
Employees2,5001,081
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BBIO has outperformed ALNY by 78.7 percentage points over the past year.
  • Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
  • BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +65.19%).

About Alnylam Pharmaceuticals

ALNY stock →

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

ALNY vs BBIO FAQ

Which is bigger, Alnylam Pharmaceuticals or BridgeBio Pharma?

Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $14.81B for BridgeBio Pharma (BBIO).

Which stock has performed better over the past year, ALNY or BBIO?

BBIO returned +11.63% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.

Are Alnylam Pharmaceuticals and BridgeBio Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons